间皮瘤生物标志物：寻求验证的发现

Mesothelioma Biomarkers: Discovery in Search of Validation.

作者信息

Pass Harvey I, Alimi Marjan, Carbone Michele, Yang Haining, Goparaju Chandra M

机构信息

Research, Department of Cardiothoracic Surgery, General Thoracic Surgery, NYU Langone Medical Center, 530 First Avenue, 9V, New York, NY 10016, USA.

Department of Cardiothoracic Surgery, NYU Langone Medical Center, 530 First Avenue, 9V, New York, NY 10016, USA.

出版信息

Thorac Surg Clin. 2020 Nov;30(4):395-423. doi: 10.1016/j.thorsurg.2020.08.001. Epub 2020 Sep 14.

DOI:10.1016/j.thorsurg.2020.08.001

PMID:33012429

Abstract

Malignant pleural mesothelioma (MPM) is an asbestos-related neoplasm that can only be treated successfully when correctly diagnosed and treated early. The asbestos-exposed population is a high-risk group that could benefit from sensitive and specific blood- or tissue-based biomarkers. We review recent work with biomarker development in MPM and literature of the last 20 years on the most promising blood- and tissue-based biomarkers. Proteomic, genomic, and epigenomic platforms are covered. SMRP is the only validated blood-based biomarker with diagnostic, monitoring and prognostic value. To strengthen development and testing of MPM biomarkers, cohorts for validation must be established by enlisting worldwide collaborations.

摘要

恶性胸膜间皮瘤（MPM）是一种与石棉相关的肿瘤，只有在早期得到正确诊断和治疗时才能成功治愈。石棉暴露人群是一个高危群体，可能会从敏感且特异的血液或组织生物标志物中获益。我们回顾了MPM生物标志物开发的近期工作以及过去20年中关于最有前景的血液和组织生物标志物的文献。涵盖了蛋白质组学、基因组学和表观基因组学平台。SMRP是唯一经过验证的具有诊断、监测和预后价值的血液生物标志物。为加强MPM生物标志物的开发和测试，必须通过全球合作建立用于验证的队列。